Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) is a clinical-stage biotechnology company pioneering small molecule therapies for hematologic disorders, cancer, and immune diseases. This news hub provides investors and healthcare professionals with rigorously verified updates on RIGL's clinical developments, regulatory milestones, and strategic partnerships.
Key resources include earnings announcements, trial result disclosures, FDA submissions, and licensing agreements. Our curated collection enables stakeholders to track the progress of oral kinase inhibitors and novel therapeutic candidates through development pipelines.
Bookmark this page for centralized access to Rigel's latest scientific advancements and business updates. All content is maintained to reflect current developments while preserving historical context for longitudinal analysis of the company's progress.
Rigel Pharmaceuticals announced a 1-for-10 reverse stock split, effective June 27, 2024. This decision will reduce the total outstanding shares from approximately 175.6 million to 17.6 million, aiming to increase the per-share trading price. The reverse split was approved by stockholders on May 24, 2024, and finalized by the Board on June 15, 2024. Post-split, Rigel’s stock will trade under the same symbol (RIGL) and a new CUSIP number (766559702). The reverse split intends to enhance the company’s appeal to institutional investors and maintain Nasdaq listing compliance. No action is required from stockholders who hold shares electronically or in street name; those with physical certificates will receive instructions for the exchange. Fractional shares will be compensated with cash.
Rigel Pharmaceuticals completed the transfer of the New Drug Application (NDA) for GAVRETO® (pralsetinib), an oral targeted therapy for patients with RET fusion-positive non-small cell lung cancer (NSCLC) and advanced thyroid cancer. GAVRETO will be available in the U.S. starting June 27, 2024. The NSCLC indication is fully approved by the FDA, while the advanced thyroid indication is approved under accelerated approval. The drug will be available in 100 mg capsules priced at $11,144.58 for 60 capsules and $16,716.85 for 90 capsules. Rigel offers patient assistance programs and comprehensive support through its RIGEL ONECARE® service. The acquisition of GAVRETO’s U.S. rights from Blueprint Medicines was announced in February 2024.
Rigel Pharmaceuticals (NASDAQ: RIGL) announced multiple presentations at the EHA2024 Hybrid Congress, focusing on the efficacy of REZLIDHIA® (olutasidenib) in treating mIDH1 AML. Highlights include five-year data from a Phase 2 trial indicating significant responses in heavily pretreated patients, including those resistant to prior venetoclax regimens. REZLIDHIA showed a median overall survival of 11.6 months and a 48% overall response rate. Poster presentations demonstrated olutasidenib's effectiveness across various patient subgroups, including elderly patients and those with AML secondary to MPNs. The data support REZLIDHIA as a promising treatment for mIDH1 AML with rapid, durable responses and manageable safety profiles.
Rigel Pharmaceuticals presented three studies at the 2024 ASCO Annual Meeting highlighting the long-term efficacy of REZLIDHIA® (olutasidenib) in treating relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). The Phase 2 trial showed a 35% complete remission or partial hematologic recovery rate among 147 patients, while elderly patients (aged 75+) achieved a 31% CR/CRh rate. Additionally, Rigel presented the Phase 1b trial of R289, an IRAK1/4 inhibitor, in lower-risk myelodysplastic syndrome (LR-MDS). The studies suggest durable responses and tolerability of olutasidenib, even in difficult-to-treat cases.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that its president and CEO, Raul Rodriguez, will present a company overview at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:30 am ET in New York, NY.
The presentation will be available via live webcast on Rigel's Investor Relations website.
Founded in 1996 and based in South San Francisco, Rigel focuses on developing therapies for hematologic disorders and cancer. For more information, visit www.rigel.com.
Rigel Pharmaceuticals announces significant presentations at the upcoming 2024 ASCO and EHA Hybrid Congresses, showcasing the efficacy of their lead products, REZLIDHIA (olutasidenib) for mIDH1 AML and TAVALISSE (fostamatinib) for chronic immune thrombocytopenia (ITP).
The final five-year results from the Phase 2 trial highlight REZLIDHIA's durable responses in heavily pretreated mIDH1 AML patients. Further, REZLIDHIA proves effective in elderly, transplant-eligible, and post-MPN patients.
Additionally, data from a Phase 1b trial of R2891, an IRAK1/4 inhibitor for lower-risk myelodysplastic syndrome (LR-MDS), and real-world analyses of TAVALISSE for ITP will be presented.
These results underscore Rigel's robust hematology and oncology portfolio, promising significant benefits for patients with challenging conditions.
Rigel Pharmaceuticals, Inc. reported total revenue of $29.5 million for the first quarter of 2024, driven by strong commercial demand for TAVALISSE® and REZLIDHIA®. The company acquired GAVRETO®, a U.S. marketed product for lung and thyroid cancer, expanded its portfolio, and appointed a new Chief Medical Officer. Rigel is progressing clinical trials, collaborating with MD Anderson and CONNECT, and advancing pipeline programs. Financially, total revenue included $21.1 million from TAVALISSE sales, $4.9 million from REZLIDHIA sales, and $3.5 million from collaborations. The net loss was $8.2 million. Rigel had $49.6 million in cash and investments as of March 31, 2024.
Rigel Pharmaceuticals, Inc. will report its first quarter 2024 financial results on May 7, 2024, followed by a conference call and webcast discussing financial results and business updates. Rigel Pharmaceuticals is focused on developing therapies for hematologic disorders and cancer.
FAQ
What is the current stock price of Rigel Pharmaceuticals (RIGL)?
What is the market cap of Rigel Pharmaceuticals (RIGL)?
